References
- Dammacco F, Abbracchio M P, Gesualdo L, Goffredo F, Ronco C, Zanella A. Biosimilars and safety issues. Leuk Lymphoma 2009; 50: 656–658
- Pavlou A K, Reichert J M. Recombinant protein therapeutics – success rates, market trends and values to 2010. Nat Biotechnol 2004; 22: 1513–1519
- Woodcock J. Assessing the impact of a safe and equitable biosimilar policy in the United States. Subcommittee on health, committee on energy and commerce, US House of Representatives, Available from: http://www.fda.gov/ola/2007/policy05022007.html (last accessed 2 May 2007)
- EMEA/CHMP. Guideline on similar biological medicinal products. 2005
- Cho A, Normile D. Nobel prize in chemistry. Mastering macromolecules. Science 2002; 298: 527–528
- Koren E, Smith H W, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008; 333: 1–9
- Shankar G, Pendley C, Stein K E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007; 25: 555–561
- Rosenberg A S. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8: E501–E507
- McKoy J M, Stonecash R E, Cournoyer D, Rossert J, Nissenson A R, Raisch D W, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48: 1754–1762
- Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007; 6: 437–442